Von Hippel-Lindau Disease Tumor Suppressor (VHL) Peptide
175.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Von Hippel-Lindau Disease Tumor Suppressor (VHL) Peptide
category
Proteins and Peptides
provider
Abbexa
reference
abx269944
tested applications
P-ELISA
Description
Von Hippel-Lindau Disease Tumor Suppressor (VHL) Peptide is a synthetic peptide.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Von Hippel-Lindau Disease Tumor Suppressor (VHL) |
| Host | Synthetic |
| Recommended Dilution | BL (predicted): 0.5 mg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Observed MW | Sequence Fragment: Internal region: C-RSLVKPENYRRLD |
| Size 1 | 100 µg |
| Form | Lyophilized Reconstitute in deionized water. |
| Tested Applications | P-ELISA |
| Buffer | Prior to lyophilization: Deionized water. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Gene ID | 7428, 22346, 24874 |
| NCBI Accession | NP_000542.1, NP_937799.1 |
| Background | Protein VHL |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
Related Products
Human VHL (Von Hippel-Lindau disease tumor suppressor) ELISA Kit
Ver Producto
VHL antibody
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor(HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2.
Ver Producto